EP1115412A1 - Neuro-immunophillines pour radioprotection neuronale selective - Google Patents

Neuro-immunophillines pour radioprotection neuronale selective

Info

Publication number
EP1115412A1
EP1115412A1 EP98948530A EP98948530A EP1115412A1 EP 1115412 A1 EP1115412 A1 EP 1115412A1 EP 98948530 A EP98948530 A EP 98948530A EP 98948530 A EP98948530 A EP 98948530A EP 1115412 A1 EP1115412 A1 EP 1115412A1
Authority
EP
European Patent Office
Prior art keywords
neuroimmunophilin
ionizing radiation
radiation
neurons
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98948530A
Other languages
German (de)
English (en)
Other versions
EP1115412A4 (fr
Inventor
Marcus Keep
Eskil Elmér
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1115412A1 publication Critical patent/EP1115412A1/fr
Publication of EP1115412A4 publication Critical patent/EP1115412A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the preferred route may vary depending on the condition of the patient.
  • the formulary drug can be manufactured and distributed in unit-dose or multi-dose containers, such as sealed glass or plastic ampoules, vials, bottles and bags as a liquid, and in a dry state requiring only the addition of sterile liquid, for example water, saline or dextrose solutions, immediately prior to use.
  • sterile liquid for example water, saline or dextrose solutions
  • Extemporaneous solutions and suspensions for injection can be prepared from powders and tablets of the kind above described.
  • the formulary drug generally contains from 0.1 to 90% of the treatment medication by weight of the total composition. Amounts of from 0.0001 mg to 200 mg/kg, or preferably 0.001 to 50 mg/kg, of body weight per day for parenteral administration and 0.001 to 150 mg/kg, preferably 0.01 to 60mg/kg, of body weight per day for enteral administration, can be given to improve neuro-radioprotection. Nevertheless, it could be necessary to alter those dosage rates, depending on the condition, weight, and individual reaction of the subject to the treatment, the type of formulary drug in which the treatment medication is administered and the mode in which the administration is carried out, and the stage of the disease process or interval of administration. It may thus be sometimes adequate to use less than the before stated minimum dose, while in other instances the upper limit must be surpassed to obtain therapeutic results.
  • a patient with a primary brain tumor such as an astrocytoma, anaplastic astrocytoma or glioblastoma multiforme receives X-radiation therapy to the brain for a series of daily treatments over two months.
  • This radiation field is wide and include large areas of normal brain in addition to the normal neurons adjacent to tumor.
  • the patient is given a series of doses of neuroimmunophilin ligand. This reduces side effects of cognitive decline, brain swelling, nausea, headaches and radiation necrosis. This increases the chances for cure or control of tumor growth.
  • Example 15 A person is pregnant and the fetus is exposed to radiation. To reduce the damage to developing fetal neurons and brain, and reduce brain damage and mental retardation of the surviving child, a dose of neuroimmunophilin ligand is administered.
  • Example 15 A person is pregnant and the fetus is exposed to radiation. To reduce the damage to developing fetal neurons and brain, and reduce brain damage and mental retardation of the surviving child, a dose of neuroimmunophilin ligand is administered.
  • a one or two part capsule is prepared by placing the formulary drug in a one or two part gelatine capsule.
  • Sterile injectable concentrate formulary drug is diluted 1 ml in 10 ml saline so that it may be administered by infusion or by injection into artery, vein, brain, spine or cerebrospinal fluid spaces.
  • a one or two part capsule is prepared by placing the formulary drug in a one or two part gelatine capsule.
  • the formulary drug is sterilized by heat or radiation and then placed in a sealed container such as glass in doses of 1 or 5 ml.
  • Sterile injectable concentrate formulary drug is diluted 1 ml in 10 ml saline so that it may be administered by infusion or by injection into artery, vein, brain, spine or cerebrospinal fluid spaces.
  • a one or two part capsule is prepared by placing the formulary drug in a one or two part gelatine capsule.
  • the formulary drug is sterilized by heat or radiation and then placed in a sealed container such as glass in doses of 1 or 5 ml.
  • Sterile injectable concentrate formulary drug is diluted 1 ml in 10 ml saline so that it may be administered by infusion or by injection into artery, vein, brain, spine or cerebrospinal fluid spaces.
  • the formulary drug is sterilized by heat or radiation & then placed in a sealed container such as glass in doses of 1 or 5 ml.
  • Sterile injectable concentrate formulary drug is diluted 1 ml in 10 ml saline so that it may be administered by infusion or by injection into artery, vein, brain, spine or cerebrospinal fluid spaces.
  • Example 25
  • a one or two part capsule is prepared by placing the formulary drug in a one or two part gelatine capsule.
  • the formulary drug is sterilized by heat or radiation & then placed in a sealed container such as glass in doses of 1 or 5 ml.
  • Sterile injectable concentrate formulary drug is diluted 1 ml in 10 ml saline so that it may be administered by infusion or by injection into artery, vein, brain, spine or cerebrospinal fluid spaces.
  • a one or two part capsule is prepared by placing the formulary drug in a one or two part gelatine capsule.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne un procédé et des produits pharmaceutiques permettant de protéger sélectivement les neurones contre les dégâts provoqués par le rayonnement ionisant, indépendamment de la source d'irradiation. Ce procédé est particulièrement utile pour protéger sélectivement les neurones normaux, mais non les cellules cérébrales tumorales, contre les effets dommageables du rayonnement ionisant.
EP98948530A 1998-09-23 1998-09-23 Neuro-immunophillines pour radioprotection neuronale selective Withdrawn EP1115412A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/020040 WO2000016794A1 (fr) 1998-09-23 1998-09-23 Neuro-immunophillines pour radioprotection neuronale selective

Publications (2)

Publication Number Publication Date
EP1115412A1 true EP1115412A1 (fr) 2001-07-18
EP1115412A4 EP1115412A4 (fr) 2004-12-15

Family

ID=22267931

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98948530A Withdrawn EP1115412A4 (fr) 1998-09-23 1998-09-23 Neuro-immunophillines pour radioprotection neuronale selective

Country Status (10)

Country Link
EP (1) EP1115412A4 (fr)
JP (1) JP2002526453A (fr)
CN (1) CN1322136A (fr)
AP (1) AP2001002113A0 (fr)
AU (1) AU766095B2 (fr)
BR (1) BR9816047A (fr)
CA (1) CA2345378A1 (fr)
HK (1) HK1040617A1 (fr)
IL (1) IL142120A0 (fr)
WO (1) WO2000016794A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036145A2 (fr) 2000-10-31 2002-05-10 Pharma Mar, S.A. Kahalalide f
WO2005103255A1 (fr) * 2004-03-25 2005-11-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recepteur formylpeptide (fpr) utilise en tant que cible pour une therapie anti-gliome malin
US11745029B2 (en) 2018-05-30 2023-09-05 Zap Surgical Systems, Inc. Radiosurgical neuromodulation close to critical structures

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022104A1 (fr) * 1995-01-20 1996-07-25 Elmer Eskil Traitement de l'ischemie cerebrale et de degats cerebraux a l'aide d'un agent neuroprotecteur

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3089350B2 (ja) * 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022104A1 (fr) * 1995-01-20 1996-07-25 Elmer Eskil Traitement de l'ischemie cerebrale et de degats cerebraux a l'aide d'un agent neuroprotecteur

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0016794A1 *

Also Published As

Publication number Publication date
EP1115412A4 (fr) 2004-12-15
AU9508198A (en) 2000-04-10
WO2000016794A1 (fr) 2000-03-30
CN1322136A (zh) 2001-11-14
CA2345378A1 (fr) 2000-03-30
IL142120A0 (en) 2002-03-10
BR9816047A (pt) 2003-01-07
JP2002526453A (ja) 2002-08-20
HK1040617A1 (zh) 2002-06-21
AP2001002113A0 (en) 2001-06-30
AU766095B2 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
AU712974B2 (en) Treatment of cerebral ischemia and cerebral damage with neuroprotective agent
Kaku et al. Superselective intra-arterial infusion of papaverine for the treatment of cerebral vasospasm after subarachnoid hemorrhage
Abigerges et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea
McEwen et al. Treatment of migraine with intramuscular chlorpromazine
CA2061270C (fr) Methode et appareil pour traiter les blessures de reperfusion
US20040147433A1 (en) Neuroimmunophilins for selective neuronal radioprotection
AU766095B2 (en) Neuroimmunophilins for selective neuronal radioprotection
NZ510739A (en) Neuroimmunophilins for selective neuronal radioprotection
JP2655694B2 (ja) 自己免疫起源の脱髄性疾患、特に多発性硬化症を処置するための医薬組成物
MXPA01003029A (en) Neuroimmunophilins for selective neuronal radioprotection
RU2222343C2 (ru) Нейроиммунофилины для селективной противолучевой защиты нейронов
Bojö et al. Involvement of vasoactive intestinal polypeptide in gastric reflex relaxation
Stancioiu et al. Post-stroke recovery of motor function with a new combination of medicines-A pilot study
EP1091750B1 (fr) Composition pharmaceutique cerebrospinale et vasculaire et procede de preparation de ladite composition
Clarke et al. Confusion and paranoia associated with oral tocainide
US3885030A (en) Medicine comprising lysine by-products
RU2155608C2 (ru) Способ комплексной интенсивной терапии ожоговых больных с сочетанным применением стресс-протекторных, адаптогенных препаратов и внутривенного лазерного облучения крови
Lee et al. High incidence of local venous reactions to esorubicin
RU2066190C1 (ru) Способ восстановления объема циркулирующей крови
Tripathi et al. Vincristine-Potent Mitotic Inhibitor
Waxman Management of depression.
MacKenna Psoralens.
Gauvin Neuro-behavioral effects of intra cranial subarachnoid infusion of somatostatin in cercopithecus aethiops

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010417

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010417;LT PAYMENT 20010417;LV PAYMENT 20010417;MK PAYMENT 20010417;RO PAYMENT 20010417;SI PAYMENT 20010417

A4 Supplementary search report drawn up and despatched

Effective date: 20041029

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 39/00 B

Ipc: 7A 61K 38/12 B

Ipc: 7A 61K 38/00 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060619